ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CPT Concepta Plc

1.98
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Concepta Plc LSE:CPT London Ordinary Share GB00BYZ2R301 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.98 1.90 2.20 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Concepta PLC Change of Registered Office (8658W)

14/02/2017 1:45pm

UK Regulatory


Concepta (LSE:CPT)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Concepta Charts.

TIDMCPT

RNS Number : 8658W

Concepta PLC

14 February 2017

14 February 2017

Concepta plc

("Concepta" or the "Company")

Change of Registered Office

Concepta plc (AIM:CPT), the UK healthcare company targeting the personalised mobile health market with a primary focus on women's fertility, announces that its registered office has changed with effect from the 15(th) February 2017 to:

1 Park Row

Leeds

LS1 5AB

ENDS

Enquiries:

Concepta plc

Adam Reynolds, Chairman

Tel: +44 (0) 7785 908158

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin / Mark Brady

Tel: +44 (0)20 368 3550

Beaufort Securities Limited (Broker)

Jon Belliss

Tel: +44 (0)20 7382 8300

Yellow Jersey PR Limited (Financial PR)

Felicity Winkles / Joe Burgess / Francesca Hillier

Tel: +44 (0) 7748 843 871

About Concepta Plc:

Concepta plc is a pioneering UK healthcare company that has developed a proprietary platform and products targeted at the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility*.

Founded in 2013, Concepta has developed a revolutionary flagship product 'myLotus' for home self-testing that helps women with unexplained infertility to conceive.

myLotus is the only consumer product which allows both quantitative and qualitative measurements of a woman's personal hCG and LH hormone levels in an easy to use home test to facilitate higher conception rates and early diagnosis of any fertility problems. Competitor products currently only allow qualitative measurement and are based on the 'average woman'.

Concepta has a defined route to market for its new 'myLotus' product with Regulatory approvals for launch in China in place for H1 2017 and CE-Marking for UK and Europe to follow later in 2017. The revenue potential of the Chinese and EU infertility market is worth c.GBP600m per annum for the company.

*Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.

This information is provided by RNS

The company news service from the London Stock Exchange

END

CROEADALFLLXEFF

(END) Dow Jones Newswires

February 14, 2017 08:45 ET (13:45 GMT)

1 Year Concepta Chart

1 Year Concepta Chart

1 Month Concepta Chart

1 Month Concepta Chart

Your Recent History

Delayed Upgrade Clock